Gilead’s Kite gets FDA nod for Tecartus to treat relapsed or refractory MCL

This article was originally published here

Tecartus, earlier known as KTE-X19, is claimed to be the first and only approved chimeric antigen receptor (CAR) T cell therapy to treat relapsed or refractory MCL. Tecartus,

The post Gilead’s Kite gets FDA nod for Tecartus to treat relapsed or refractory MCL appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply